You are here: Industry Insights > Market News > M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

pharmaceutical-technologyAugust 21, 2017

Tag: Guanhao Biotech , Cancer Genetics , Alvogen

Favorites

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen - Pharmaceutical Technology

Chinese biotechnology company Guanhao Biotech plans to acquire a 53.4% stake in two pharmaceutical companies based in China for CNY266m ($39.95m).

US-based pharmaceutical company Cancer Genetics Inc (CGI) plans to acquire Australian preclinical oncology services provider vivoPharm for $12m. The acquisition is expected to strengthen CGI’s business.

South Korean pharmaceutical company Alvogen plans to acquire Russian pharmaceutical firm Omega Bittner from Irish healthcare company Perrigo Company.

The acquisition will strengthen Alvogen’s business in Russia.

Previous:Cadila Pharma observes ‘Swachhta Pakhwada’

Next:Cancer Research UK and Newcastle University extend drug discovery partnership with Astex

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

You may like
More>>

M&As this week: Guanhao Biotech, Cancer Genetics, Alvogen

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

You may likeMore>>

You may like
More>>